RUNX2 and neoplasm: We also observed increased expressions of effector genes (Tnf, Gzma, and Gzmd) and key T cell activation TFs (Nfatc1, Stat4, Runx1, Runx2, and Nfkb1) in the medium expanded CD8+ Tex after decitabine plus anti–PD-1 combination treatment, although it is still being investigated whether the active bystander TILs contributed to better tumor control with PD-1 blockade therapy.